Development of a Point-of-Care Diagnostic for Influenza Detection with Antiviral Treatment Effectiveness Indication

Video   Jun 23, 2015


Currently, diagnosis of influenza is performed either through either polymerase chain reaction (PCR) or through rapid antigen detection assays. The rapid antigen detection assays currently available are highly specific but not very sensitive, and lack the ability to show if the strain of influenza detected is susceptible to antiviral agents, such as Tamiflu and Relenza. The ability to rapidly determine if a patient has an infectious disease and what type of treatment the infection will respond to, would significantly reduce the treatment decision time, shorten the impact of symptoms, and minimize transfer to others. In this study, a point-of-care style µPAD (microfluidic paper-based diagnostic) for influenza has been developed with the ability to determine antiviral susceptibility of the strain for treatment decision. The assay exploits the enzymatic activity of surface proteins present on all influenza strains, and potential false positive responses can be mitigated. A simple nasal swab sample diluted in water is added to the device, the sample is distributed to 4 different reagent zones, and development of the enzymatic substrate under different buffer conditions takes place on bottom of the device. Analysis can be performed by eye or through a colorimetric image analysis smartphone app.


Recommended Videos

Here’s What We Learned From 83,000 Brain Scans


The most important lesson from 83,000 brain scans.


PerkinElmer VICTOR Nivo Multimode Plate Reader - So Much Science So Little Bench Space


The VICTOR Nivo system: The next big thing in plate readers is now the smallest.


How does a medicine get from the lab to patients?


How is a new medicine for your disease approved by the European Medicines Agency?



Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Diagnostics Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free